The Access SARS-CoV-2 IgG antibody test features market-leading sensitivity and specificity. Sensitivity and specificity matter because tests without extremely high accuracy could lead to large numbers of incorrect results, potentially resulting in dangerous consequences.
- The Access SARS-CoV-2 IgG assay is being validated against over 1,000 negative broad population-based samples—significantly more than the number of samples required by the FDA for Emergency Use Authorization
- 100% sensitivity and 99.8% specificity—one of the highest dual rates for SARS-CoV-2 antibody tests in the market
- Releasing a standalone SARS-CoV-2 IgG test and not a combined IgG-IgM may be more clinically informative
The Access SARS-CoV-2 IgG Antibody Test is manufactured and approved for use by the Therapeutic Goods Administration (TGA) .
Buy the Access SARS-CoV-2 IgG Antibody Test for Detecting SARS-CoV-2 for Your WorkPlace
If your company or organisation is interested in rapid testing solutions, contact us today for help procuring the Access SARS-CoV-2 IgG Antibody Test for Detecting SARS-CoV-2 for detecting SARS-CoV-2 or other rapid tests authorised by the Therapeutic Goods Administration (TGA) .
If you’re interested in rapid testing solutions, contact us today for a quote. You can also place an order for the Access SARS-CoV-2 IgG Antibody Test for Detecting SARS-CoV-2 or other rapid tests approved by the TGA.
Our team at Rapid Tests Australia can also assist with implementing a rapid testing program to protect your workplace from the risks of COVID-19.
